Risk Detection in Neuroscience Trials: Are You Missing Early Warning Signs?

With billions of neurons, the brain is the most complex organ in the body, so it’s not surprising that neuroscience clinical trials—more so than trials in other medical specialties—face major challenges. Despite volume of research and funding, neuroscience clinical trials continue to fail for many reasons. Among them, lack of reliable biomarkers, subjective outcome parameters, and high placebo response rates.

For developers of neuroscience therapies, appropriately leveraging risk detection early during a clinical trial can significantly increase the ability to intervene and apply remediation timely, thereby improving the probability of success for the clinical study. In this webinar, you will learn:

  • Best practices for robust risk assessment and establishing key risk indicators (KRIs)
  • Strategies for mitigating data quality challenges in neuroscience studies
  • The benefits of a clinical specialist conducting regular, blinded data reviews of study KRIs
  • The use and impact of technology in enhancing the risk detection process
Meet Our Speakers:

Andreas Schreiner, M.D.
Senior Vice President, Medical Affairs, Neuroscience and Analgesia

Adam Simmons
Executive Director, Program Strategy, Neuroscience